Simultaneous determination of nalbuphine and its prodrug sebacoly dinalbuphine ester in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in humans

Biomedical Chromatography

Volumn 27, Issue 7, 2013, Pages 831-837

  Huang, Pei Wei ^a   Liu, Hung Ta ^a   Hsiong, Cheng Huei ^a   Pao, Li Heng ^a,b   Lu, Chih Cherng ^c   Ho, Shung Tai ^d   Hu, Oliver Yoa Pu ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Nalbuphine; Sebacoyl dinalbuphine ester (SDE); UPLC MS MS

Indexed keywords

COLUMN CHROMATOGRAPHY; DICHLOROMETHANE; ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; ITERATIVE METHODS; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN);

HUMAN PLASMAS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; NALBUPHINE; PHARMACOKINETIC STUDIES; PRODRUGS; SEBACOYL DINALBUPHINE ESTER; SIMULTANEOUS DETERMINATIONS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPLC-MS/MS;

ESTERS;

ESTER DERIVATIVE; ETHYLMORPHINE; NALBUPHINE; PRODRUG; SEBACOLY DINALBUPHINE ESTER; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STABILITY; ELECTROSPRAY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84878959254     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2867     Document Type: Article

References (19)

1. Aitkenhead AR, Lin ES and Achola KJ. The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers. British Journal of Clinical Pharmacology 1988; 25: 264-268.
2. Broekkamp CL, Oosterloo SK and Rijk HW. Prodrug behaviour of nicotinoylmorphine esters. The Journal of Pharmacy and Pharmacology 1988; 40: 434-437.
3. Cai X, Zhong B, Su B, Xu S and Guo B. Development and validation of a rapid LC-MS/MS method for the determination of Jcc76, a novel antitumor agent for breast cancer, in rat plasma and its application to a pharmacokinetics study. Biomedical Chromatography 2012; 26: 1118-1124.
4. Davies GG and From R. A blinded study using nalbuphine for prevention of pruritus induced by epidural fentanyl. Anesthesiology 1988; 69: 763-765.
5. Dube LM, Beaudoin N, Lalande M and McGilveray IJ. Determination of nalbuphine by high-performance liquid chromatography with electrochemical detection: application to clinical samples from postoperative patients. Journal of Chromatography 1988; 427: 113-120.
6. He G, Massarella J and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clinical Pharmacokinetics 1999; 37: 471-484.
7. Hemstrom CA, Evans RL and Lobeck FG. Haloperidol decanoate: a depot antipsychotic. Drug Intelligence & Clinical Pharmacy 1988; 22: 290-295.
8. Ho ST, Wang JJ, Hu OY, Chiang PS and Lee SC. Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. Journal of Chromatography. B, Biomedical Applications, 1996; 678: 289-296.
9. Keegan M and Kay B. Detection of nalbuphine in plasma: an improved high-performance liquid chromatographic assay. Journal of Chromatography 1984; 311: 223-226.
10. Lake CL, DiFazio CA, Duckworth EN, Moscicki JC, Engle JS and Durbin CG. High-performance liquid chromatographic analysis of plasma levels of nalbuphine in cardiac surgical patients. Journal of Chromatography 1982; 233: 410-416.
11. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
12. Nicolle E, Michaut S, Serre-Debeauvais F and Bessard G. Rapid and sensitive high-performance liquid chromatographic assay for nalbuphine in plasma. Journal of Chromatography. B, Biomedical Applications 1995; 663: 111-117.
13. Pao LH, Hsiong CH, Hu OY and Ho ST. High-performance liquid chromatographic method for the simultaneous determination of nalbuphine and its prodrug, sebacoyl dinalbuphine ester, in dog plasma and application to pharmacokinetic studies in dogs. Journal of Chromatography. B, Biomedical Sciences and Applications 2000; 746: 241-247.
14. Pao LH, Hsiong CH, Hu OY, Wang JJ and Ho ST. In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine. Drug Metabolism and Disposition: the Biological Fate of Chemicals 2005; 33: 395-402.
15. Picker MJ. Kappa agonist and antagonist properties of mixed action opioids in a pigeon drug discrimination procedure. The Journal of Pharmacology and Experimental Therapeutics 1994; 268: 1190-1198.
16. Plumb R, Castro-Perez J, Granger J, Beattie I, Joncour K and Wright A. Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry 2004; 18: 2331-2337.
17. Pugh GC, Drummond GB, Elton RA and Macintyre CC. Constant i.v. infusions of nalbuphine or buprenorphine for pain after abdominal surgery. British Journal of Anaesthesia 1987; 59: 1364-1374.
18. US Food and Drug Administration. FDA Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
19. Weinstein SH, Alteras M and Gaylord J. Quantitative determination of nalbuphine in plasma using electron-capture detection. Journal of Pharmaceutical Sciences 1978; 67: 547-548.